Ademetionine (SAMe): Mechanism of Action

Ademetionine, better known in the United States as SAMe, is a molecule every cell in your body makes. In parts of Europe and Asia it is prescribed for liver conditions, while in the US it is sold over the counter as a dietary supplement for mood and joint health. Our editorial team explains how SAMe works at the biochemical level, why it is studied for liver protection, and what the evidence does and does not support.

What ademetionine is

S-adenosylmethionine was discovered by the Italian biochemist Giulio Cantoni in 1952. It is formed in the body from the amino acid methionine and ATP by the enzyme methionine adenosyltransferase (MAT). The liver is the main site of both production and consumption.

SAMe sits at the crossroads of three metabolic pathways: transmethylation, transsulfuration and aminopropylation. Through these, it influences gene expression, cell membrane function, antioxidant defense and the synthesis of polyamines involved in cell growth.

The molecule is chemically unstable, which made early pharmaceutical development difficult. Stable salt forms, such as SAMe tosylate disulfate and SAMe 1,4-butanedisulfonate, made oral and injectable products possible.

In chronic liver disease, the activity of MAT often falls, reducing the liver's ability to produce its own SAMe. This observation underpins the rationale for supplementation in liver conditions.

Methylation: the universal donor

SAMe's best-known role is as the principal methyl donor in the body. It transfers a methyl group (CH₃) to DNA, RNA, proteins, phospholipids and neurotransmitters in reactions catalyzed by methyltransferase enzymes.

DNA methylation helps regulate which genes are switched on or off. Phospholipid methylation contributes to the formation of phosphatidylcholine, a key component of cell membranes and of the lipoproteins that export fat from the liver.

In the brain, methylation reactions involving SAMe participate in the synthesis and metabolism of neurotransmitters such as serotonin, dopamine and norepinephrine. This connection is the basis of research into SAMe for depression.

After donating its methyl group, SAMe becomes S-adenosylhomocysteine (SAH), which is then converted to homocysteine. Homocysteine can be recycled back to methionine using folate and vitamin B12, or diverted into the transsulfuration pathway.

Transsulfuration and glutathione

When homocysteine enters the transsulfuration pathway, enzymes that depend on vitamin B6 convert it into cysteine. Cysteine is the rate-limiting building block for glutathione, the liver's most important intracellular antioxidant.

Glutathione neutralizes reactive oxygen species and binds toxic metabolites, including the reactive intermediate produced when the liver processes high doses of acetaminophen. Low glutathione leaves liver cells more vulnerable to oxidative and chemical injury.

SAMe also acts as a regulator: it activates cystathionine beta-synthase, the first enzyme in transsulfuration, steering homocysteine toward glutathione production when SAMe levels are adequate.

Through the aminopropylation pathway, decarboxylated SAMe donates groups for the synthesis of polyamines such as spermidine and spermine, which play roles in cell growth and tissue repair.

Clinical research in liver disease and beyond

The most cited liver trial is by Mato and colleagues, published in 1999, which studied patients with alcoholic liver cirrhosis. Among those with less advanced disease, SAMe at 1,200 mg per day for two years was associated with lower combined mortality or need for transplant, though the overall result was not statistically significant. A later Cochrane review found insufficient evidence to support or refute SAMe for alcoholic liver disease.

SAMe has also been studied for intrahepatic cholestasis, including cholestasis of pregnancy, where it is used in some countries. Results suggest modest benefits on itching and liver tests, but ursodeoxycholic acid is generally favored in current guidelines.

For depression, several randomized trials and meta-analyses suggest SAMe may outperform placebo, and some studies examined it as an add-on to antidepressants. The evidence quality is considered low to moderate, and it is not a substitute for established treatment.

• Liver disease: biologically plausible, clinical evidence limited and mixed.
• Cholestasis: used in some countries, modest effects.
• Depression: some positive trials, low to moderate certainty.
• Osteoarthritis: older trials suggest pain relief comparable to NSAIDs in some studies, with fewer GI effects.

Athletes sometimes ask about SAMe for "liver support" during use of hepatotoxic substances. There is no evidence that SAMe makes such substances safe, and relying on it this way can delay recognition of real liver damage.

Regulatory status and safety

In the United States, SAMe has been available as a dietary supplement since 1999. It is not FDA-approved as a drug for any condition. In several European and Asian countries, ademetionine is registered as a prescription medicine for intrahepatic cholestasis and related liver conditions.

Studies have used oral doses ranging from about 400 to 1,600 mg per day, depending on the indication. Because SAMe degrades with moisture and heat, enteric-coated tablets in blister packs are generally more stable than loose powders.

SAMe is usually well tolerated. Common side effects include nausea, digestive upset, insomnia and anxiety. Its serotonergic activity raises concern about serotonin syndrome when combined with antidepressants, triptans or other serotonergic drugs.

People with bipolar disorder should avoid SAMe unless supervised by a psychiatrist, as it has been associated with triggering mania. It may also interact with levodopa used in Parkinson's disease. Data in pregnancy outside medical settings are limited.

Editorial team conclusions

Ademetionine is a central metabolic molecule that donates methyl groups, feeds glutathione synthesis and supports polyamine production.

These mechanisms explain why it is studied for liver protection, cholestasis, mood and joint health, though clinical evidence remains modest.

In the US it is a dietary supplement, not an approved liver drug, and it should not be used to justify exposure to liver-toxic substances.

For related reading, our editorial team recommends articles on liver function tests for athletes, glutathione and N-acetylcysteine, and homocysteine and B vitamins.

References

1. Mato JM, Cámara J, Fernández de Paz J, et al. S-adenosylmethionine in alcoholic liver cirrhosis: a randomized, placebo-controlled, double-blind, multicenter clinical trial. J Hepatol. 1999;30(6):1081–1089.
2. Rambaldi A, Gluud C. S-adenosyl-L-methionine for alcoholic liver diseases. Cochrane Database Syst Rev. 2006;(2):CD002235.
3. Lu SC, Mato JM. S-adenosylmethionine in liver health, injury, and cancer. Physiol Rev. 2012;92(4):1515–1542.
4. Cantoni GL. The nature of the active methyl donor formed enzymatically from L-methionine and adenosinetriphosphate. J Am Chem Soc. 1952;74(11):2942–2943.
5. Sharma A, Gerbarg P, Bottiglieri T, et al. S-adenosylmethionine (SAMe) for neuropsychiatric disorders: a clinician-oriented review of research. J Clin Psychiatry. 2017;78(6):e656–e667.
6. Anstee QM, Day CP. S-adenosylmethionine (SAMe) therapy in liver disease: a review of current evidence and clinical utility. J Hepatol. 2012;57(5):1097–1109.